Anticorps Recombinant de lapin anti-IL-17RA

IL-17RA Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

Non conjugué

CloneNo.

241891G7

N° de cat : 98271-1-RR

Synonymes

CD217, IL17RA, 241891G7, CANDF5, CDw217



Applications testées

Résultats positifs en cytométriehuman peripheral blood leukocytes

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98271-1-RR cible IL-17RA dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène IL-17RA Protéine recombinante Eg2317
Nom complet interleukin 17 receptor A
Masse moléculaire calculée 866 aa, 96 kDa
Numéro d’acquisition GenBankBC011624
Symbole du gène IL17RA
Identification du gène (NCBI) 23765
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

IL-17 is a proinflammatory cytokine. IL-17 can signal as homodimers or heterodimers through a heterodimeric receptor formed by IL-17 receptor A (IL-17RA) and IL-17 receptor C (IL-17RC) subunits. IL-17RA is ubiquitously expressed in both the epithelial and hematopoietic cell compartments. IL-17/IL-17RA signaling plays an important physiological role in regulating the mucosal host defense against invading microorganisms, but it can also play pathogenic roles in several inflammatory or autoimmune conditions; furthermore, it has been described as pro-tumorigenic in several cancer types.

Protocole

Product Specific Protocols
FC protocol for IL-17RA antibody 98271-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}